Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment
Authors
Keywords
-
Journal
CELL CYCLE
Volume 13, Issue 20, Pages 3292-3301
Publisher
Informa UK Limited
Online
2014-10-31
DOI
10.4161/15384101.2014.949501
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protein kinase A is a target for aging and the aging heart
- (2016) Linda C Enns et al. Aging-US
- Novel strategies of protecting non-cancer cells during chemotherapy: Are they ready for clinical testing?
- (2015) Zbigniew Darzynkiewicz Oncotarget
- Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs
- (2015) Ingeborg van Leeuwen et al. Oncotarget
- Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture
- (2015) Pasha Apontes et al. Oncotarget
- Xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer cells likely represents a laboratory artifact
- (2015) Jiawen Yang et al. Oncotarget
- The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes
- (2015) Ruchi Singhal et al. Oncotarget
- Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer
- (2015) Helen M. Coley et al. Oncotarget
- LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer
- (2015) Francesca Lovat et al. Oncotarget
- HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells
- (2015) Dong-Qin Chen et al. Oncotarget
- Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer
- (2015) Nader Al Nakouzi et al. Oncotarget
- Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle
- (2014) Yanting Zhu et al. CELL CYCLE
- Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics
- (2013) Li Chen et al. BMC CANCER
- Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer
- (2013) Rui Henrique et al. BMC GENOMICS
- Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival
- (2013) Frédérique Braun et al. CELL CYCLE
- Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy
- (2013) Serena Giovinazzi et al. CELL CYCLE
- Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
- (2012) Man Yu et al. CANCER AND METASTASIS REVIEWS
- Identification of a novel role of Septin 10 in paclitaxel-resistance in cancers through a functional genomics screen
- (2012) Mingli Xu et al. CANCER SCIENCE
- Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection
- (2011) A. Biffi et al. BLOOD
- Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer
- (2011) N. Syed et al. CANCER RESEARCH
- The PKA paradox: Is Bim the answer?
- (2011) Andrew M. Coley et al. CELL CYCLE
- Long-Distance Effects of Insertional Mutagenesis
- (2011) Ruchi Singhal et al. PLoS One
- A Chemosensitization Screen Identifies TP53RK, a Kinase that Restrains Apoptosis after Mitotic Stress
- (2010) D. Peterson et al. CANCER RESEARCH
- Class III -Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
- (2010) G. Ploussard et al. CANCER RESEARCH
- Transposon-based mutagenesis identifies short RIP1 as an activator of NFκB
- (2010) Maupali Dasgupta et al. CELL CYCLE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- The microtubule as a breast cancer target
- (2010) Gerald M. Higa Breast Cancer
- Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
- (2009) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- USP15 plays an essential role for caspase-3 activation during Paclitaxel-induced apoptosis
- (2009) Mingli Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer Cells
- (2009) S. De et al. CANCER RESEARCH
- Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NF B
- (2009) T. Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Natural Human Retrovirus Efficiently Complements Vectors Based on Murine Leukemia Virus
- (2008) Beihua Dong et al. PLoS One
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now